For years, injectable biologics have been the gold standard for moderate to severe psoriasis. But as patients grow weary of needles, scheduling injections, and managing side effects, many are asking: can I switch to an oral pill? The answer in 2026 is a resounding yes — thanks to breakthrough oral therapies like Icotyde, Sotyktu, and Otezla. This guide walks you through the benefits, risks, and safe transition strategies for switching from injections to oral psoriasis treatment.
Why Patients Want to Switch
Several factors drive the desire to switch from injections to oral medications:
- Injection fatigue: Weekly or monthly injections can become mentally and physically draining.
- Needle phobia: Fear of needles affects millions and can lead to treatment non-adherence.
- Travel and lifestyle inconvenience: Injections require clinic visits or careful self-administration, which can disrupt travel or work schedules.
- Desire for simplicity: A once-daily pill fits seamlessly into daily routines.
- Cost and insurance: Some oral options may have better coverage or lower out-of-pocket costs.
- New oral options: For the first time, oral medications are delivering biologic-level results — making the switch medically viable.
The 2026 Oral Psoriasis Landscape
2026 marks a turning point in psoriasis treatment with several oral therapies now available. These options offer a non-injectable alternative with strong efficacy and improved safety profiles.
| Medication | Drug Class | Dosing | IGA 0/1 | PASI 90 (Wk 16) | Key Notes |
|---|---|---|---|---|---|
| Icotyde (icotrokinra) | Oral IL-23 receptor antagonist | Once daily 200mg (empty stomach) | ~70% | ~55% | First oral with biologic-level results; minimal immunosuppression |
| Sotyktu (deucravacitinib) | TYK2 inhibitor | Once daily | ~50% | ~35% | No immunosuppression monitoring required; well-tolerated |
| Otezla (apremilast) | PDE4 inhibitor | Twice daily | ~18% | ~10% | Non-immunosuppressive; GI side effects common |
What You're Giving Up by Switching
While oral options are promising, it's important to understand what you may lose when switching from injectable biologics:
| Medication | Drug Class | Dosing | PASI 90 (Wk 16) |
|---|---|---|---|
| Skyrizi (risankizumab) | IL-23p19 antibody | Every 12 weeks | 70–73% |
| Tremfya (guselkumab) | IL-23p19 antibody | Every 8 weeks | ~65% |
| Cosentyx (secukinumab) | IL-17A inhibitor | Every 4 weeks | ~60% |
| Stelara (ustekinumab) | IL-12/23 inhibitor | Every 12 weeks | ~45% |
Realistic expectations are key: while oral therapies like Icotyde are closing the gap, they still don't match the high PASI 90 rates of top injectable biologics. Icotyde is the first oral to approach biologic-level clearance, but for patients needing maximum skin clearance or those with psoriatic arthritis, injectables may still be the best choice.
How to Switch Safely
Switching from an injection to an oral medication is not something to do on your own. Always consult your dermatologist first.
- Do not stop injections abruptly: This can trigger a flare-up or rebound psoriasis.
- Start oral while tapering or after last injection wears off: The safest approach is to begin the oral medication when the next injection would be due.
Switching Timeline
- Skyrizi → Icotyde: Start Icotyde 12 weeks after your last Skyrizi injection (when the next dose would be due).
- Cosentyx → Icotyde: Start 4 weeks after your last Cosentyx injection.
- Tremfya → Icotyde: Start 8 weeks after your last Tremfya injection.
- Stelara → Icotyde: Start 12 weeks after your last Stelara injection.
Expect a possible flare during the transition — keep topical corticosteroids on hand. Monitor your skin closely and schedule follow-ups with your dermatologist at 4, 8, and 16 weeks to assess your response.
Who Should NOT Switch
If you're well-controlled on your current injectable treatment with no side effects and no desire to change, there's no medical reason to switch. As the saying goes: if it ain't broke, don't fix it. Additionally, patients with:
- Severe psoriasis requiring maximum clearance
- Psoriatic arthritis (where biologics have proven joint and structural benefits)
should carefully consider whether switching is appropriate. The long-term data for oral agents in joint protection is still emerging.
The Bottom Line
2026 is a pivotal year for psoriasis treatment. For the first time, patients can switch from injections to oral pills with confidence — thanks to Icotyde's breakthrough efficacy. However, this decision should always be made in partnership with your dermatologist. Consider your disease severity, lifestyle, and treatment goals. The future of psoriasis care is more flexible than ever.
For more insights: